Cytori Therapeutics Q2 2009 financial results
September 08, 2017
???During the second quarter, we continued to establish a foundation of Celution?® customers in Europe and Asia through system sales and we experienced an increase in re-orders of consumables,??? said Christopher J. Calhoun, chief executive officer of Cytori. ???Additionally, we have completed enrollment in our cardiovascular disease clinical trials, surpassed 70% enrollment for our post-marketing breast reconstruction study, strengthened our balance sheet, and gained important clarity on our U.S. regulatory pathway. Due to the nature of the sales cycle for our Celution?® and Stem Source?® products, we expect to experience annual revenue growth interspersed with fluctuations in quarterly growth. Based on our current sales pipeline, we maintain our goal for $10 million in product revenue for 2009.???
Conference Call & Shareholder Letter
Cytori??™s second quarter update and financial results shareholder letter is now available on its Investor Relations homepage at ir.cytoritx. Cytori will host a conference call at 10:30 a.m. Eastern Time today to discuss these results. The audio webcast of the conference call may be accessed under ???Webcasts??? in the Investor Relations section of Cytori's website (www.cytoritx). The webcast will be available live and by replay two hours after the call and archived for 90 days. A telephone replay will be available for one week, accessible at +1 (303) 590-3030 (PIN: 4126637).
www.cytoritx